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The study evaluated routine laboratory tests (com-
plete blood count, electrolytes, liver function 
tests, creatinine with estimated glomerular fil-
tration rate and uric acid) and a set of selected 
biomarkers (growth hormone, insulin-like growth 
factor 1, NT-proBNP, sST2, MMP-9, CRP, procolla-
gen III, MPO, NGAL). Prognostic value of the eval-
uated tests was assessed based on the 6 months 
follow-up of 179 patients with HF applying ei-
ther all-cause death or heart transplantation as 
primary endpoint and secondary composite end-
point including death, heart transplantation, jus-
tified antiarrhythmic cardioverter-defibrilator in-
tervention or hospitalization due to HF. Most of 
biomarkers selected by the authors for evaluation 
were the subject of numerous studies assessing 
their diagnostic and prognostic value (TABLE).1-3,5 
The results obtained in the study by Rywik et al. 
support the final conclusion that biomarkers do 
not outweigh routine laboratory evaluation in 
the prediction of outcome in HF patients. They 
found that only uric acid and sodium levels were 
independent predictors of the primary endpoint 
and eGFR of secondary endpoint. Of the evalu-
ated biomarkers only NT-proBNP and sST2 were 
associated with prognosis in the studied group.
The results and conclusions presented by Ry-
wik et al.,4 being in contrast to many published 
data,1,2 are interesting and not surprising. Some 
explanations may be found in the study itself. 
The follow-up period was short and the number 
of studied patients achieving particular endpoints 
was small. An important issue is the proper selec-
tion of cut-off values for the diagnostic/prognos-
tic biomarker evaluation. In this study, it could be 
difficult because many of the obtained test results 
were within or near the reference ranges. Some of 
the biomarkers selected for evaluation were ex-
tensively studied and found to have high prognos-
tic value whereas others were not. Nonetheless, 
almost all biomarkers evaluated by Rywik et al.4 
are considered emerging or candidate markers. 
Only natriuretic peptides and cardiac troponins 
are recommended in clinical practice guidelines 
developed by European and American cardiology 
societies for the use in HF.6,7 It should be stressed 
Heart failure (HF) is currently one of the most 
challenging health care problems worldwide and 
will remain so in the nearest future. Despite years 
of successful research and advances in clinical 
practice, the diagnosis of HF, determination of 
prognosis, and selection of treatment still need 
to be improved. The currently available diagnostic 
tools including laboratory tests and echocardiog-
raphy or other imaging studies do not fully meet 
clinicians’ needs. The rapidly growing area of HF 
research are biomarker studies. Biomarkers may 
be defined as substances that can be measured 
in body fluids and that are involved in HF, which 
is considered to be a multiorgan disease process 
rather than affecting only the heart or circula-
tion. Thus biomarkers may reflect abnormal reg-
ulation of organ systems and tissue damage asso-
ciated with HF.1,2 Currently, more than 100 estab-
lished and candidate biomarkers are being inves-
tigated to evaluate their usefulness in the diagno-
sis, prognosis, and treatment of HF. The majority 
of papers published over the last 20 years report 
on the prognostic value of one or more evaluat-
ed biomarkers.2 The most extensively investigat-
ed biomarkers in HF include natriuretic peptides 
(B-type natriuretic peptide [BNP], N-terminal 
proBNP, mid-regional pro-atrial natriuretic pep-
tide), soluble ST2 (sST2), growth differentiation 
factor 15, cardiac troponins, markers of inflam-
mation and oxidative stress (C-reactive protein 
[CRP], tumor necrosis factor α, interleukin 6, 
myeloperoxidase [MPO]), markers of extracellu-
lar matrix modelling (matrix metalloproteinas-
es [MMP-2, MMP-3, MMP-9] and their tissue in-
hibitors (TIMPs, galectin 3, collagen precursors), 
neurohormones (endothelin 1, urocortin 1, argi-
nine vasopressin represented by copeptin, adre-
nomedullin (ADM) represented by midregion-
al pro-ADM), renal tubular markers (neutrophil 
gelatinase-associated lipocalin [NGAL], N-ace-
tyl-beta-d-glucosaminidase, kidney injury mol-
ecule 1), and, recently, microRNAs.1-3
In the current issue of the Polish Archives of In-
ternal Medicine, Rywik et al.4 reported the prog-
nostic value of novel biomarkers in comparison 
with broad biochemical evaluation in HF patients. 
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that the same guidelines strongly recommend 
the use of routine laboratory tests in the diag-
nosis of HF and assessment of disease severity 
and prognosis.6,7 All the other biomarkers men-
tioned above and presented in the TABLE are still 
being investigated in numerous experimental and 
clinical trials, which sometimes yield conflicting 
results.1-3 The use of HF biomarkers still requires 
analytical improvement, mostly standardization 
of immunoassays and harmonization of results5 
as well as a comprehensive diagnostic/prognostic 
evaluation.1,2 Although much evidence has been 
reported, there is still much to be discovered in 
the field of biomarkers in HF. The huge scientific 
effort reflected by a rapidly growing number of 
publications on biomarkers will soon undoubt-
edly provide added value to the still imperfect di-
agnosis of HF.2,8 The study reported by Rywik et 
al.4 is part of this research and debate.
TABLE Reported diagnostic and prognostic value of heart failure biomarkers1,2
Biomarker Diagnosis Prognosis
BNP / NT-proBNP ++++ ++++
cardiac troponins + ++++
sST2 + ++++
GDF-15 – +++
TNF-α – ++
CRP – ++
IL-6 – ++
MPO – ++
galectin 3 – +++
endothelin 1 – ++
copeptin – ++
MR-proADM – ++++
NGAL – ++++
RDW – ++++
microRNAs + –
Abbreviations: BNP, B-type natriuretic peptide; CRP, C-reactive protein; GDF-15, growth 
differentiation factor 15; IL-6, interleukin 6; MPO, myeloperoxidase; MR-proADM, 
midregional pro-adrenomedullin; NGAL, neutrophil gelatinase-associated lipocalin; 
NT-proBNP, N-terminal pro-B-type natriuretic peptide; RDW, red blood cell distribution 
width; sST2, soluble ST2; TNF-α, tumor necrosis factor α
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